Fig. 3: Virologic success in the ADVANCE Trial divided by the presence or absence of WHO-defined pretreatment major drug mutations and by use of efavirenz- or dolutegravir-based regimen. | Nature Communications

Fig. 3: Virologic success in the ADVANCE Trial divided by the presence or absence of WHO-defined pretreatment major drug mutations and by use of efavirenz- or dolutegravir-based regimen.

From: Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

Fig. 3

Results are for virologic success defined by our primary outcome (a), secondary outcome (b), FDA 48-week Snapshot (c), and FDA 96-week Snapshot (d). Error bars indicate 95% confidence intervals around the proportion estimates. P values represent results of two-sided two-proportion Z tests.

Back to article page